Wai-Kwan Alfred Yung, M.D. - Publications

Neuro-Oncology MD Anderson Cancer Center, Houston, TX, United States 
Neuro-Oncology, Cancer Biology

72 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, et al. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology. PMID 26476729 DOI: 10.1007/s11060-015-1958-z  0.52
2015 Liu Q, Liu Y, Li W, Wang X, Sawaya R, Lang FF, Yung WK, Chen K, Fuller GN, Zhang W. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathologica. PMID 26323991 DOI: 10.1007/s00401-015-1470-8  0.52
2015 Kim SJ, Lee HJ, Kim SW, Choi HJ, He J, Wu Q, Aldape KD, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26106074 DOI: 10.1158/1078-0432.CCR-14-3195  0.52
2015 Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 372: 2481-98. PMID 26061751 DOI: 10.1056/NEJMoa1402121  0.36
2015 Turner KM, Sun Y, Ji P, Granberg KJ, Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, Shmulevich I, Yung WK, Fuller GN, Zhang W. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression. Proceedings of the National Academy of Sciences of the United States of America. 112: 3421-6. PMID 25737557 DOI: 10.1073/pnas.1414573112  0.52
2015 Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, ... ... Yung WK, et al. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro-Oncology. 17: 266-73. PMID 25239666 DOI: 10.1093/neuonc/nou155  0.52
2015 Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, et al. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro-Oncology. 17: 180-8. PMID 25165194 DOI: 10.1093/neuonc/nou154  0.52
2014 Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro-Oncology. 16: vii36-47. PMID 25313237 DOI: 10.1093/neuonc/nou226  0.52
2014 Yung WK. Imaging endpoints in brain tumor clinical trials: proceedings of the January 30, 2014 Workshop. Introduction. Neuro-Oncology. 16: vii1. PMID 25313233 DOI: 10.1093/neuonc/nou291  0.52
2014 Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. Plos One. 9: e97407. PMID 24827739 DOI: 10.1371/journal.pone.0097407  0.52
2014 Liu Q, Turner KM, Alfred Yung WK, Chen K, Zhang W. Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro-Oncology. 16: 1313-23. PMID 24811392 DOI: 10.1093/neuonc/nou058  0.52
2014 Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. Journal of Neuro-Oncology. 119: 135-40. PMID 24803001 DOI: 10.1007/s11060-014-1460-z  0.52
2014 Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL, Zhao Q. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunology Research. 2: 371-9. PMID 24764584 DOI: 10.1158/2326-6066.CIR-13-0088  0.52
2014 Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. Plos One. 9: e91216. PMID 24614622 DOI: 10.1371/journal.pone.0091216  0.52
2014 Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology. 16: 567-78. PMID 24470557 DOI: 10.1093/neuonc/not247  0.52
2014 Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells (Dayton, Ohio). 32: 301-12. PMID 24038660 DOI: 10.1002/stem.1528  0.52
2013 Yung WKA. Neuro-oncology: Past milestones and the journey ahead Neuro-Oncology. 15: 1453-1454. PMID 24174568 DOI: 10.1093/neuonc/not196  0.52
2013 Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Yung WK, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/j.cell.2013.09.034  0.52
2013 Chang S, Yung WK. New Neuro-Oncology Practice journal to launch in 2014. Neuro-Oncology. 15: 1277. PMID 24057884 DOI: 10.1093/neuonc/not160  0.52
2013 Yung WK. Higher impact, wider influence. Neuro-Oncology. 15: 1113. PMID 23966014 DOI: 10.1093/neuonc/not135  0.52
2013 Zhang C, Moore LM, Li X, Yung WK, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro-Oncology. 15: 1114-26. PMID 23877318 DOI: 10.1093/neuonc/not087  0.52
2013 Weller M, Yung WK. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro-Oncology. 15: 971. PMID 23864129 DOI: 10.1093/neuonc/not106  0.52
2013 Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro-Oncology. 15: 972-8. PMID 23857706 DOI: 10.1093/neuonc/not088  0.52
2013 Anderson MD, Theeler BJ, Penas-Prado M, Groves MD, Yung WK. Bevacizumab use in disseminated choroid plexus papilloma. Journal of Neuro-Oncology. 114: 251-3. PMID 23761024 DOI: 10.1007/s11060-013-1180-9  0.52
2013 Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 119: 2747-53. PMID 23633392 DOI: 10.1002/cncr.28031  0.52
2013 Yung WK. From GWAS risk foci to glioma molecular subclass. Neuro-Oncology. 15: 513-4. PMID 23620433 DOI: 10.1093/neuonc/not061  0.52
2013 Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. Neuro-Oncology. 15: 829-39. PMID 23502430 DOI: 10.1093/neuonc/not024  0.52
2013 Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WK. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Research. 73: 3062-74. PMID 23492364 DOI: 10.1158/0008-5472.CAN-12-2033  0.52
2013 Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN, Strausberg RL, Yao J. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2460-72. PMID 23444225 DOI: 10.1158/1078-0432.CCR-12-3708  0.52
2013 Alexander BM, Wang M, Yung WK, Fine HA, Donahue BA, Tremont IW, Richards RS, Kerlin KJ, Hartford AC, Curran WJ, Mehta MP. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). Journal of Neuro-Oncology. 111: 33-9. PMID 23086432 DOI: 10.1007/s11060-012-0987-0  0.52
2012 Theeler BJ, Yung WK, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology. 79: 1917-26. PMID 23109653 DOI: 10.1212/WNL.0b013e318271f7cb  0.52
2012 Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. Plos One. 7: e45894. PMID 23029298 DOI: 10.1371/journal.pone.0045894  0.52
2012 Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6032-9. PMID 22923449 DOI: 10.1158/1078-0432.CCR-12-1841  0.52
2012 Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. Journal of Neuro-Oncology. 108: 491-8. PMID 22426926 DOI: 10.1007/s11060-012-0847-y  0.52
2012 Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemotherapy and Pharmacology. 69: 1507-18. PMID 22392572 DOI: 10.1007/s00280-012-1854-6  0.52
2012 Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. Journal of Neuro-Oncology. 107: 487-501. PMID 22249692 DOI: 10.1007/s11060-011-0786-z  0.52
2012 Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J. Gene therapy. Handbook of Clinical Neurology. 104: 331-8. PMID 22230451 DOI: 10.1016/B978-0-444-52138-5.00021-9  0.52
2012 Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 118: 3599-606. PMID 22086614 DOI: 10.1002/cncr.26663  0.52
2012 Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 184-95. PMID 22065080 DOI: 10.1158/1078-0432.CCR-11-1558  0.52
2012 Yung WKA. A year of continued growth and success Neuro-Oncology. 14: 1-2. DOI: 10.1093/neuonc/nor225  0.52
2011 Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, Huang H, Xue J, Liu M, Wang Y, Sawaya R, Xie K, Yung WK, Medema RH, He X, et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell. 20: 427-42. PMID 22014570 DOI: 10.1016/j.ccr.2011.08.016  0.52
2011 Atkinson JM, Shelat AA, Carcaboso AM, Kranenburg TA, Arnold LA, Boulos N, Wright K, Johnson RA, Poppleton H, Mohankumar KM, Féau C, Phoenix T, Gibson P, Zhu L, Tong Y, ... ... Yung WK, et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell. 20: 384-99. PMID 21907928 DOI: 10.1016/j.ccr.2011.08.013  0.52
2011 Yung WK. New impact factor number reflects sustained and enhanced growth. Neuro-Oncology. 13: 925. PMID 21852428 DOI: 10.1093/neuonc/nor128  0.52
2011 Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-Oncology. 13: 1118-24. PMID 21813511 DOI: 10.1093/neuonc/nor110  0.52
2011 Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, et al. It is time to include patients with brain tumors in phase I trials in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3211-3. PMID 21768451 DOI: 10.1200/JCO.2011.36.6328  0.52
2011 Guan S, Shen R, Lafortune T, Tiao N, Houghton P, Yung WK, Koul D. Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy. Neuro-Oncology. 13: 748-58. PMID 21653596 DOI: 10.1093/neuonc/nor037  0.52
2011 de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4872-81. PMID 21632852 DOI: 10.1158/1078-0432.CCR-11-0271  0.52
2011 de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2689-95. PMID 21606416 DOI: 10.1200/JCO.2010.34.1636  0.52
2011 Lawrence YR, Wang M, Dicker AP, Andrews D, Curran WJ, Michalski JM, Souhami L, Yung WK, Mehta M. Early toxicity predicts long-term survival in high-grade glioma. British Journal of Cancer. 104: 1365-71. PMID 21487410 DOI: 10.1038/bjc.2011.123  0.52
2011 Kim YW, Liu TJ, Koul D, Tiao N, Feroze AH, Wang J, Powis G, Yung WK. Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM. Neuro-Oncology. 13: 367-75. PMID 21430111 DOI: 10.1093/neuonc/nor012  0.52
2011 Siker ML, Wang M, Porter K, Nelson DF, Curran WJ, Michalski JM, Souhami L, Chakravarti A, Yung WK, Delrowe J, Coughlin CT, Mehta MP. Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison. Journal of Neuro-Oncology. 104: 351-6. PMID 21221714 DOI: 10.1007/s11060-010-0500-6  0.52
2011 Liu JL, Mao Z, Gallick GE, Yung WK. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro-Oncology. 13: 184-94. PMID 21123367 DOI: 10.1093/neuonc/noq163  0.52
2011 Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 13: 143-51. PMID 21084434 DOI: 10.1093/neuonc/noq151  0.52
2011 Fueyo J, Gomez-Manzano C, Yung WK. Advances in translational research in neuro-oncology. Archives of Neurology. 68: 303-8. PMID 21059986 DOI: 10.1001/archneurol.2010.293  0.52
2010 Yung WK. The problem with cell phones...or maybe not. Neuro-Oncology. 12: 1087. PMID 20966155 DOI: 10.1093/neuonc/noq159  0.52
2010 Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-Oncology. 12: 1167-72. PMID 20729242 DOI: 10.1093/neuonc/noq100  0.52
2010 Yung WK. Impact Factor number reflects sustained high quality. Neuro-Oncology. 12: 893. PMID 20720000 DOI: 10.1093/neuonc/noq105  0.52
2010 Yung WKA. Review of the complexities of the PI3K/mTOR pathway presages similar handling of other critical topics Neuro-Oncology. 12: 763-764. PMID 20671128 DOI: 10.1093/neuonc/noq083  0.52
2010 Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology. 12: 1061-70. PMID 20615922 DOI: 10.1093/neuonc/noq072  0.52
2010 Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM, Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro-Oncology. 12: 559-69. PMID 20156803 DOI: 10.1093/neuonc/nop058  0.52
2010 Yung WK. Tumor stem cells, notch, and the news. Neuro-Oncology. 12: 115. PMID 20150377 DOI: 10.1093/neuonc/nop055  0.52
2010 Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology. 12: 95-103. PMID 20150372 DOI: 10.1093/neuonc/nop015  0.52
2010 Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro-Oncology. 12: 87-94. PMID 20150371 DOI: 10.1093/neuonc/nop017  0.52
2010 Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. Journal of Neuro-Oncology. 96: 211-7. PMID 19562255 DOI: 10.1007/s11060-009-9948-7  0.52
2010 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Reply to W. Wick et al Journal of Clinical Oncology. 28: e190-e192. DOI: 10.1200/JCO.2009.26.9472  0.52
2010 Yung WKA. Journal to shift practice on obtaining conflict of interest declarations Neuro-Oncology. 12: 619-620. DOI: 10.1093/neuonc/noq064  0.52
2010 Yung WKA. Neuro-oncology turns a page Neuro-Oncology. 12: 1. DOI: 10.1093/neuonc/nop037  0.52
2010 Dorai Z, Sawaya R, Yung WKA. Brain metastasis Oncology of Cns Tumors. 345-361. DOI: 10.1007/978-3-642-02874-8_20  0.52
2009 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4733-40. PMID 19720927 DOI: 10.1200/JCO.2008.19.8721  0.52
2009 Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro-Oncology. 11: 853-60. PMID 19293394 DOI: 10.1215/15228517-2009-010  0.52
2009 Yung WKA. Celebrating the journal's next evolutionary step Neuro-Oncology. 11: 723. DOI: 10.1215/15228517-2009-093  0.52
2009 Yung WKA. New impact factor reflects journal's growth Neuro-Oncology. 11: 457. DOI: 10.1215/15228517-2009-064  0.52
Show low-probability matches.